Overview

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-09

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.

Phase:

PHASE2

Details

Lead Sponsor:

Incyte Corporation